To investigate the underlying mechanisms of ISG20 in glioma, functional enrichment analyses were performed based on DEGs between patients with high or low expression levels of ISG20. There were 2,624 DEGs between the glioma patient subgroups classified according to the median expression level of ISG20, of which 1,392 were upregulated and 1,232 were downregulated in the subgroup expressing higher levels of ISG20 (Figure S1 and Table S4). Here, ISG20 is linked to central nervous system cancer.